These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 15657340)

  • 1. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
    Li LC; Carroll PR; Dahiya R
    J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic mechanisms in glioblastoma multiforme.
    Nagarajan RP; Costello JF
    Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
    Vaissière T; Sawan C; Herceg Z
    Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.
    Wang LG; Beklemisheva A; Liu XM; Ferrari AC; Feng J; Chiao JW
    Mol Carcinog; 2007 Jan; 46(1):24-31. PubMed ID: 16921492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.
    Baylin SB
    Novartis Found Symp; 2004; 259():226-33; discussion 234-7, 285-8. PubMed ID: 15171257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
    Grønbaek K; Treppendahl M; Asmar F; Guldberg P
    Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic alterations and cancer: new targets for therapy.
    Allen A
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylated genes as potential biomarkers in prostate cancer.
    Phé V; Cussenot O; Rouprêt M
    BJU Int; 2010 May; 105(10):1364-70. PubMed ID: 20067451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics in bladder cancer.
    Enokida H; Nakagawa M
    Int J Clin Oncol; 2008 Aug; 13(4):298-307. PubMed ID: 18704629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic mechanisms in the biology of prostate cancer.
    Schulz WA; Hoffmann MJ
    Semin Cancer Biol; 2009 Jun; 19(3):172-80. PubMed ID: 19429481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epigenome and cancer: new possibilities of cancer prevention and therapy?].
    Paluszczak J; Baer-Dubowska W
    Postepy Biochem; 2005; 51(3):244-50. PubMed ID: 16381168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic mechanisms in cancer.
    Banerjee HN; Verma M
    Biomark Med; 2009 Aug; 3(4):397-410. PubMed ID: 20477485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetics in prostate cancer: biologic and clinical relevance.
    Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
    Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic changes in cancer.
    Grønbaek K; Hother C; Jones PA
    APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.